Reviva Pharmaceuticals Holdings, Inc. (RVPH)
Market Closed
31 Aug, 20:00
OTC PINK OTC PINK Primary $
0. 48
-0.04
-7.4253%
$
6.15M Market Cap
- P/E Ratio
- Div Yield
39,628 Volume
-1.35 Eps
$ 0.52
Previous Close 
Want to track RVPH and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Reviva Pharmaceuticals: Upcoming Events May Generate Excitement, But Cash Is Low
Reviva Pharmaceuticals aims to improve schizophrenia treatment with Brilaroxazine, showing promising Phase 3 data but needing funding for a second trial to meet FDA requirements. Reviva should announce open label safety and biomarker efficacy data from its previous Phase 3 trial any day now. The company faces financial challenges, requiring either dilution or a partnership to fund the next Phase 3 trial and continue operations.
Seekingalpha | 1 year ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH
NEW YORK, NY / ACCESSWIRE / June 1, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Reviva Pharmaceuticals Holdings, Inc. ("Reviva" or the "Company") (NASDAQ:RVPH). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Accesswire | 2 years ago
